C12N 2760/18271
Demonstrated in vivo effect
C12N2760/18271 (Demonstrated in vivo effect) appears on 13 US grants and 23 published applications in this corpus.
Search patents in C12N- Granted patents
- 13
- Published applications
- 23
- Assignees
- 10
- Inventors
- 33
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 2 |
| 2014 | 1 | 0 |
| 2015 | 2 | 2 |
| 2016 | 1 | 1 |
| 2017 | 1 | 2 |
| 2018 | 2 | 0 |
| 2019 | 0 | 3 |
| 2020 | 0 | 0 |
| 2021 | 0 | 3 |
| 2022 | 2 | 1 |
| 2023 | 1 | 3 |
| 2024 | 0 | 0 |
| 2025 | 2 | 3 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- CD8-specific antibody constructs and compositions thereof7 Jul 2026US 12,674,180 B2Sana Biotechnology, Inc.
- Vaccines against Nipah virus, and methods of using same15 Jul 2025US 12,357,683 B2The Wistar Institute of Anatomy and Biology
- Henipavirus vaccine21 Jan 2025US 12,201,682 B2CureVac AG
- Nipah virus envelope pseudotyped lentiviruses and methods of their use14 Feb 2023US 11,576,982 B2The Regents of the University of California
- CD8-specific antibody constructs and compositions thereof27 Dec 2022US 11,535,869 B2Sana Biotechnology, Inc.
- Cd8-specific antibody constructs and compositions thereof10 Sep 2026US 2026/0265780 A1Sana Biotechnology, Inc.
- Rapid Acting Vaccine Against Nipah Virus24 Apr 2025US 2025/0127878 A1Board of Regents, The University of Texas System
- Henipavirus vaccine20 Mar 2025US 2025/0090652 A1CureVac AG
- Nipah henipavirus virus replicon particles and their use27 Feb 2025US 2025/0064918 A1The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Nipah virus envelope pseudotyped lentiviruses and methods of their use14 Sep 2023US 2023/0285591 A1The Regents of the University of California
Most cited
By later US patents
- Henipavirus vaccine9US 11,524,066 B2CureVac AG · 2022
- Nipah virus envelope pseudotyped lentiviruses and methods of their use7US 10,064,958 B2The Regents of the University of California · 2018
- Nipah virus envelope pseudotyped lentiviruses and methods of their use6US 11,576,982 B2The Regents of the University of California · 2023
- Nipah virus envelope pseudotyped lentiviruses and methods of their use6US 9,486,539 B2The Regents of the University of California · 2016
- CD8-specific antibody constructs and compositions thereof1US 11,535,869 B2Sana Biotechnology, Inc. · 2022